Amgen, Hospira Challenge $70M Biosimilar Judgment
Hospira Inc. urged a Delaware federal court Monday to overturn a $70 million patent infringement verdict regarding Hospira's production of a biosimilar for Amgen Inc.'s anemia treatment Epogen, while Amgen argued...To view the full article, register now.
Already a subscriber? Click here to view full article